These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9631975)

  • 21. A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey.
    Maki KC; Davidson MH; Dicklin MR
    Can J Cardiol; 2006 Mar; 22(4):315-22. PubMed ID: 16568156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
    Weizel A; Sawicki PT
    MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study.
    Tomasik T; Jozwiak J; Windak A; Rygiel K; Mastej M; Smithson WH; Mathers N; Tomaszewski M; Kaess BM; Tykarski A; Konduracka E; Grzeszczak W; Lukas W
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):287-96. PubMed ID: 21450675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NCEP's new guidelines at a glance. National Cholesterol Education Program.
    Benedict M
    Health Care Food Nutr Focus; 2002 Aug; 18(12):8-9. PubMed ID: 12192777
    [No Abstract]   [Full Text] [Related]  

  • 25. [Drug therapy of hypercholesterolemia].
    Schwandt P; Richter WO
    Wien Klin Wochenschr; 1995; 107(18):544-8. PubMed ID: 7483641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The heart of the matter. National guidelines urge more aggressive cholesterol treatment.
    Leake NB
    Adv Nurse Pract; 2002 Jan; 10(1):42-7; quiz 48-9. PubMed ID: 12420511
    [No Abstract]   [Full Text] [Related]  

  • 27. Update on lipid-lowering therapy and LDL-cholesterol targets.
    Wiviott SD; Cannon CP
    Nat Clin Pract Cardiovasc Med; 2006 Aug; 3(8):424-36. PubMed ID: 16874355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol: precursor to many lipid disorders.
    Jones PH
    Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic lifestyle changes and drug treatment for high blood cholesterol in China and application of the Adult Treatment Panel III guidelines.
    Muntner P; Gu D; Reynolds RF; Wu X; Chen J; Whelton PK; He J
    Am J Cardiol; 2005 Nov; 96(9):1260-5. PubMed ID: 16253594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The "healthy" patient with hypercholesterolemia].
    Klose G
    Med Klin (Munich); 2005 Feb; 100(2):99-106; quiz 107-8. PubMed ID: 15711905
    [No Abstract]   [Full Text] [Related]  

  • 31. [Aggressive therapy and combination therapy in severe hyperlipidemia].
    Kostner KM
    Wien Med Wochenschr; 1999; 149(5-6):146-8. PubMed ID: 10408007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Gotto AM; Whitney E; Stein EA; Shapiro DR; Clearfield M; Weis S; Jou JY; Langendörfer A; Beere PA; Watson DJ; Downs JR; de Cani JS
    Eur Heart J; 2000 Oct; 21(19):1627-33. PubMed ID: 10988016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
    Van Ganse E; Laforest L; Alemao E; Davies G; Gutkin S; Yin D
    Curr Med Res Opin; 2005 Sep; 21(9):1389-99. PubMed ID: 16197657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP).
    Ito MK; Stolley SN; Morreale AP; Lin JC; Marcus DB
    Am J Health Syst Pharm; 1999 Jun; 56(11):1107-13. PubMed ID: 10385458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rising to the challenge of the new NCEP ATP III guidelines: exceeding current therapeutic limitations.
    Brewer HB
    Am J Manag Care; 2002 Feb; 8(2 Suppl):S23-8; discussion S45-7. PubMed ID: 11855698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis].
    MMW Fortschr Med; 2004 Mar; 146(13):64-5. PubMed ID: 15219142
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. National cholesterol education program (NCEP) guidelines too complex.
    Feeman WE
    Prev Cardiol; 2005; 8(3):188. PubMed ID: 16108130
    [No Abstract]   [Full Text] [Related]  

  • 40. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada.
    Frohlich J; Fodor G; McPherson R; Genest J; Langner N
    Can J Cardiol; 1998 Apr; 14 Suppl A():17A-21A. PubMed ID: 9594929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.